CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies have?
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies has 78 citations in the OpenAlex counts ScholarIQ stores.
When was CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies published?
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies has 2021 year in the ScholarIQ index.
What is the open-access status of CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies?
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies has gold oa status in the ScholarIQ index.
What is the DOI of CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies?
The DOI for CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies is on the source record.
What is the PMID of CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies?
The PMID for CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies is on the source record.
What is the OpenAlex record for CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies?
The OpenAlex for CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies is on the source record.